MARKET

KDNY

KDNY

Chinook Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.46
+0.58
+4.18%
Opening 13:01 05/27 EDT
OPEN
13.99
PREV CLOSE
13.88
HIGH
14.68
LOW
13.84
VOLUME
449.24K
TURNOVER
4.43M
52 WEEK HIGH
19.85
52 WEEK LOW
10.48
MARKET CAP
797.86M
P/E (TTM)
-7.0358
1D
5D
1M
3M
1Y
5Y
GRPN, GNCA and LAB among mid-day movers
=Gainers: BlackSky Technology (BKSY) +93%. StoneMor (STON) +51%. Genocea Biosciences (GNCA) +35%. Hoegh LNG Partners (HMLP) +31%. Caleres (CAL) +27%. Evelo Biosciences (EVLO) +20%. Spire Global (SPIR) +17%. Groupon (GRPN)
Seekingalpha · 2d ago
Hot Stocks: Kim Kardashian lifts BYND; BNS, ATHM rise on earnings; KDNY falls on offering
Kim Kardashian's influence played a role in Wednesday's midday trading, lifting shares of Beyond Meat (NASDAQ:BYND), which climbed on news of an endorsement deal with celebrity influencer Kim Kardashian. In
Seekingalpha · 2d ago
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 2d ago
BGFV, TWOU and ASO among pre market losers
Verrica Pharmaceuticals (VRCA) -54% downgraded at RBC as FDA snubs skin disease therapy. Super Group (SGHC) -14% on Q1 results. DICK'S Sporting Goods (DKS) -13% on dire forecast for full-year sales. Better Therapeutics (BTTX) -13%. Academy
Seekingalpha · 2d ago
Wedbush Adjusts Chinook Therapeutics Price Target to $36 From $38, Maintains Outperform Rating
MT Newswires · 2d ago
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers The Singing Machine Company, Inc. (NASDAQ: MICS) shares rose 47.3% to $4.05 in pre-market trading.
Benzinga · 2d ago
Chinook Therapeutics stock slides on $105M equity offering
Chinook Therapeutics (NASDAQ:KDNY) shares have slid 7% pre-market after the biopharmaceutical company priced its $105M share and warrant offering. The offering consists of 6,428,572 shares of common stock priced at $14/share. Underwriters
Seekingalpha · 2d ago
Chinook Therapeutics Priced ~6.4M Share Offering @$14/Share
Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to the public of $14.00 per share.
Benzinga · 2d ago
More
No Data
Learn about the latest financial forecast of KDNY. Analyze the recent business situations of Chinook Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average KDNY stock price target is 32.43 with a high estimate of 48.00 and a low estimate of 25.00.
High48.00
Average32.43
Low25.00
Current 15.42
EPS
Actual
Estimate
-0.74-0.51-0.28-0.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 159
Institutional Holdings: 49.72M
% Owned: 90.10%
Shares Outstanding: 55.18M
TypeInstitutionsShares
Increased
37
4.98M
New
13
3.73M
Decreased
31
2.88M
Sold Out
12
4.80M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
President/Chief Executive Officer/Director
Eric Dobmeier
Chief Financial Officer
Eric Bjerkholt
Chief Operating Officer
Tom Frohlich
Chief Scientific Officer
Andrew King
Lead Director/Independent Director
Jerel Davis
Independent Director
Srinivas Akkaraju
Independent Director
William Greenman
Independent Director
Michelle Griffin
Independent Director
Ross Haghighat
Independent Director
Manesh Krishnan
Independent Director
Dolca Thomas
No Data
No Data
About KDNY
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing precision medicines for kidney diseases. The Company's development programs consist of Atrasentan, BION-1301 and CHK-336. Atrasentan is a potent and selective endothelin A receptor antagonist that are developed for the treatment of proteinuric glomerular diseases. BION-1301 is an investigational humanized IgG4 monoclonal antibody that blocks APRIL binding to both the B-cell maturation antigen (BCMA), and transmembrane activator and CAML interactor (TACI), receptors, as a disease-modifying therapy for Immunoglobulin A Nephropathy (IgAN). CHK-336 is a liver-targeted oral small molecule lactate dehydrogenase (LDHA), inhibitor, which are developed for the treatment of primary hyperoxaluria.

Webull offers kinds of Chinook Therapeutics Inc stock information, including NASDAQ:KDNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KDNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KDNY stock methods without spending real money on the virtual paper trading platform.